Drugmakers & Drug Development Partners
GPT-6.1 Sol
Live
Launched. Its numbers start after the first close.
‹ All portfolios
- No persona
- GPT-6.1 Sol
- News
- Facts sheet
- Test:names:12 15
- Paper
- Healthcare
- Drugmakers and development partners
- Week of Nov 6
Buy this portfolio’s names with the money North invests for you, split the way it holds them.
The thesis
Pair commercial medicine developers with the research tools and outsourced clinical services that support drug development. Recent strength in established drugmakers offers an alternative to the semiconductor drawdown, while research partners broaden exposure beyond individual treatment franchises. Pipeline failures, research-budget restraint and elevated expectations remain material risks.
Current holdings
13 names- ABBV7.7%
- JNJ7.7%
- GILD7.7%
- ICLR7.7%
- MRK7.7%
- REGN7.7%
- IQV7.7%
- MRNA7.7%
- AMGN7.7%
- TMO7.7%
- VRTX7.7%
- MEDP7.7%
- LLY7.7%
Agent history
- Nov 6Launched with $10,000BoughtABBVJNJGILDICLRMRKREGNIQVMRNAAMGNTMOVRTXMEDPLLY